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ABSTRACT 
Objective: Development and characterization of self-nanoemulsifying drug delivery system for sertraline hydrochloride (SNEDDS).  
Methods: Solubility of sertraline hydrochloride in various vehicles were determined, and ternary phase diagrams were constructed using a suitable 
oil, surfactant and cosurfactant system to find out the most efficient self emulsification system.  
Results: Capmul® and Lauroglycol® were selected as an oil phase, Tween 80 and Cremophor® as surfactant and Transcutol®
 
INTRODUCTION 
 as cosurfactant due to 
their high solublization effect. Various formulations were prepared by simple mixing followed by vortexing. The systems were assessed for droplet 
size, light absorbance, drug release and emulsification effect. Optimized SNEDDS compositions of oil to surfactant/cosurfactant content did not 
show phase separation in 0.1N HCl and water, with droplet size varying from 21 nm to 153 nm, which indicates the formation of homogeneous 
stable nano emulsion in both media. In vitro dissolution data showed surprisingly significant enhancement of dissolution rate of sertraline HCl in 
form of SNEDDS compared to the drug per se. 
Conclusion: These results confirm the potentiality of SNEDDS formulation to improve sertraline HClsolubilization and In vitro release. 
Keywords: Self-nanoemulsifying drug delivery systems (SNEDDS), Sertraline HCl, Surfactant, Cosurfactant. 
Sertraline HCl – a selective serotonin re-uptake inhibitor (SSRI) – is 
indicated for the treatment of depression and anxiety disorders, 
including obsessive-compulsive disorder, panic disorder and post-
traumatic stress disorder. It is considered suitable for the treatment 
of depressive symptoms in elderly patients, including those with 
Alzheimer’s disease (AD), as it has minimal anticholinergic activity 
and is essentially devoid of cardiovascular effects[1]. Furthermore, 
sertraline HCl may be useful in the management of other 
behavioural problems experienced by AD patients that are likely 
mediated by the serotonergic system, such as anxiety, irritability and 
aggression[2]. 
Sertraline is administered orally in a daily dose of 50 mg. But various 
problems are associated with its oral delivery such as extensive first-
pass metabolism, gastrointestinal disturbances such as nausea, dry 
mouth, diarrhea, decreased appetite etc., and ultimately its poor 
bioavailability (40–45%), which required this drug to be taken in 
high doses in order to maintain adequate plasma levels[3]. Sertraline 
hydrochloride is practically insoluble in water. Its bioavailability is 
expected to be limited by its dissolution rate. To overcome these 
problems, various formulation strategies are exploited including the 
use of surfactants, lipids, permeation enhancers, micronisation, salt 
formation, cyclodextrin complexation, nanoparticles and solid 
dispersions[4]. 
Oral-based drug delivery system is the most common way to deliver 
drugs into the blood stream. The water-soluble drugs can diffuse 
freely and easily in gastrointestinal tract and they have a high 
bioavailability. However, more and more drugs being discovered 
nowadays with the advances in biotechnology and pharmaceutical 
technology are oil-soluble[5]. One way to deliver oil-soluble drugs is 
to incorporate the drug into an inert lipid vehicle, such as 
nanoemulsions, oils[6], surfactant dispersions[7] and liposomes[8]. 
Nano emulsions are isotropic, thermodynamically stable systems 
and the droplets of nano emulsions are of very small size. Self-
nanoemulsifying drug delivery system (SNEDDS) is a pre-mixture of 
drug, oil, surfactant and cosurfactant that can be used to deliver oil-
based drugs. Upon gentle shaking and gastric juice dilution in stomach, it 
can form nanoemulison spontaneously [9]. The current study was aimed 
at developing and characterizing SNEDDS for sertraline HCl so as to 
improve dissolution rate-limited absorption of the drug. 
MATERIALS AND METHODS 
Materials 
Sertraline hydrochloride was kindly donated by Hipharma 
pharmaceuticals, Egypt. Transcutol® P (2-(2- ethoxyethoxy) 
ethanol), Capryol® 90 (Propylene glycol monocaprylate), Labrafil® M 
2125 CS (Linoleoyl polyoxyl-6 glycerides) and Lauroglycol® 90 
(propylene glycol monolaurate; PGML) were kindly supplied by 
Gattefossé, France. Captex® 355 EP/NF (triglycerides of 
caprylic/capric acid; Captex®) and Capmul® MCM EP (glycerol 
monocaprylocaprate; Capmul®) were gifted by ABITEC Corporation, 
USA. Tween 80® (polyoxyethylenesorbitan mono oleate) was 
purchased from Oxford Laboratory Reagent, India. Cremophor® ELP 




The solubility of sertraline HCl in various oils, surfactants and 
cosurfactants was determined by adding an excess amount of drug 
to 2 ml of selected vehicles separately in 5 ml stoppered vials, and 
mixed using a vortex mixer. The vials were then kept at 25 ± 1.0 0
One of the most important characteristics of SNEDDS is the change 
that occurs when the system is diluted (since it will be diluted by 
body fluids after administration), which may cause drug 
C in 
an isothermal shaker for 72 h to attain equilibrium. The equilibrated 
samples were removed from the shaker and centrifuged at 3,000 
rpm for 15 min. The supernatant was taken and filtered through a 
0.45 µm membrane filter. The concentration of sertraline HCl was 
determined spectrophotometrically at 273.4 nm. 
Construction of ternary phase diagram 
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precipitation due to the loss of solvent capacity [10]. Therefore, the 
phase behavior of each SNEDDS needs to be carefully studied using 
the phase diagram as a guide. On the basis of the solubility studies of 
drug, Capmul®, PGML® and Captex® were selected as oil phase. 
Tween 80 and Cremophore EL® were used as surfactants and 
Transcutol P®
11
 was used as cosurfactant. Oil, surfactant and 
cosurfactant were grouped in different combination for phase 
studies [ ]. Surfactants and cosurfactant (Smix) were mixed in 
different ratios (1:1, 2:1, 3:1 and 4:1). Mixture of oil and Smix was 
prepared at ratios (w/w) of 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7; 2:8, 
1:9 and 0:10 in vials. A visual observation was made immediately for 
spontaneity of emulsification, clarity, phase separation and 
precipitation of drug and excipients [12]. An aliquot (0.2 ml) of the 
formulation was introduced into 300 ml of double distilled water in 
a glass beaker at 37 °C, and the contents were mixed gently with a 
magnetic stirrer at 100 rpm. The resultant emulsions were stored 
for 48 h at ambient temperature and observed for clarity, phase 
separation, drug precipitation and coalescence of droplets. 
Emulsions showing phase separation, cracking or coalescence of oil 
droplets were judged as unstable emulsions. All the studies were 
repeated thrice with and without drug with similar observations 
made between repeats. Phase diagram was constructed identifying 
self emulsifying region using Triplot v1-4 software. 
Preparation of SNEDDS of sertraline HCl 
A series of SNEDDS formulations were prepared using oil, surfactant 
and cosurfactant. In all the formulations, the amount of sertraline 
HCl was kept constant (i. e. 25 mg). The amount of SNEDDS should 
be such that it would solubilize the drug (single dose) completely. 
Sertraline HCl (25 mg) was added to the mixture, then the 
components were mixed by gentle stirring and vortex mixing, and 
heated at 37̊C. The mixture was stored at room temperature until 
used. So prepared SNEDDS were the concentration of oil, surfactant, 
cosurfactant and drug [13]. 
Characterization of SNEDDS 
Thermodynamic stability test 
To overcome the problem of a metastable formulation, 
thermodynamic stability tests were performed. Selected 
formulations were subjected to heating / cooling cycles. Six cycles 
between the refrigerator temperature (0 0C) and 40 0C were 
performed with storage at each temperature for not less than 48 h. 
Those formulations, which were stable after these temperature 
cycles, were centrifuged at 5,000 rpm for 30 min and observed for 
phase separation, creaming or cracking. Formulations which showed 
no phase separation were exposed for three freeze thaw cycles 
between -210C and +25 0
14
C with storage at each temperature for not 
less than 48 h. The formulations were then observed for phase 
separation[ ]. 
Cloud point measurement 
The cloud point measurement was carried out for the stable 
formulations as reported earlier [15]. The formulation was diluted 
up to 100 fold with distilled water and kept in a water bath which 
was maintained at a temperature of 25 °C with gradual increase of 
temperature at a rate of 5 °C/min and the corresponding cloud point 
temperatures were recorded at first sign of turbidity by visual 
observation. 
Determination of the emulsification time 
In order to determine the emulsification time (the time needed to 
reach the emulsified and homogeneous mixture, upon dilution), 1 g 
of each formulation was added to 200 mL of 0.1N HCl at 37 ◦
One gram of SNEDDS formulation containing 25 mg of sertraline HCl 
was diluted to 100 mL with distilled water in a flask and was mixed 
gently by inverting the flask. The droplet size, zeta potential and the 
polydispersity index (PDI) of the SNEDDS formulations were 
determined by photon correlation spectroscopy that analyze the 
fluctuation in light scattering due to the Brownian motion of the 
droplets as function of time using a ZetasizerNano series (Malvern 
Instruments, USA). Light scattering was monitored at 25 
C with 
gentle agitation using magnetic stirrer. The formulations were 
assessed visually according to the rate of emulsification and the final 
appearance of the emulsion. 
Droplet size, particle size distribution and zeta potential 
analysis  
0C at a 900
14
 
angle [ ]. 
Transmission electron microscopy 
SNEDDS was diluted with distilled water at 1:100 ratios and mixed 
by slight shaking. A drop of diluted SNEDDS was applied to a 300 
mesh copper grid and was left for 1 min. The morphology and 
structure of the nanoemulsion formed were studied using 
transmission electron microscopy (TEM). A combination of bright-
field imaging at increasing magnification and of diffraction modes 
was used to reveal the form and size of the nanoemulsion. 
Drug content 
The total amount of drug in the formulation was analyzed by 
dissolving the formulation in 10 mL of ethanol. This solution was 
vortexed for 10 min in vortex mixture. The mixture was centrifuged 
at 15,000 rpm for 10 min. Then the supernatant was filtered through 
Whatman filter paper. The concentration of sertraline HCl in the 
filtrate was analyzed spectrophotometrically at 273.4 nm. 
 In vitro drug release study of SNEDDS 
The quantitative estimation of release was performed by  In vitro 
dissolution study of all the formulations, which was determined 
using USP XXIV dissolution apparatus II. The paddles were rotated at 
100 rpm. One gram of SNEDD formulations containing 25 mg of 
sertraline HCl was put in hard gelatin capsule (0 size). The 
dissolution vessel contained 900 mL of acetate buffer (pH 4.5) as the 
dissolution medium maintained at 37 ± 0.5 0
Most important criteria for selection of components in any 
formulation are their pharmaceutical acceptability and are 
prerequisite for exploiting the advantages of nanoemulsions. It has 
been established that only very specific pharmaceutical excipient 
combinations lead to efficient nanoemulsion formulations [
C. A 5 mL sample was 
withdrawn at 5, 10, 15, 30, 45 and 60 minutes. The withdrawn 
sample was replenished with 5 mL of fresh blank medium. The 
withdrawn samples were filtered and analyzed for the drug 
spectrophotometrically at 273.4 nm. Optimized formulation release 
was compared with that of plain sertraline HCl to evaluate the 
release enhancement by SNEDDS. 
RESULTS AND DISCUSSION 
Solubility study 
16]. 
The solubility of sertraline HCl in different oils was determined, as 
for drug substances with a log P value around 3 to 5, there is no clear 
trend regarding the type of oil that will cause the highest increase in 
solubility [17]. Solubility of sertraline HCl was determined in six 
different oils to choose the oil showing highest solubility for the 
drug. Results of solubility of sertraline HCl in various oils are shown 
in table 1 and The highest solubility of sertraline HCl was observed 
in PGML® (21.87 mg/ml), followed by Captex® (13 mg/ml) and 
Capmul® (10.51 mg/ml), hence these oils were chosen as oil phase 
for preparation of SNEDDS.  
Also, results of solubility of sertraline HCl in various surfactants and 
cosurfactants are also shown in table 1. The solubility of sertraline 
HCl is highest in Tween 80® (59.40 mg/ml), followed by 
Cremophor® (32.50 mg/ml) and Transcutol®
Based on the results of solubility study, six phase diagrams were 
constructed, namely; system I: Capmul
 and hence these are 
chosen as surfactant and cosurfactant combinations for the 
preparation of SNEDDS. 
Construction of ternary phase diagrams 
®/Cremophor®/Transcutol®; 
system II: Capmul®/Tween80®/Transcutol®; system III: 
Captex®/Cremophor®/Transcutol®; system IV: Captex®/Tween 
80®/Transcutol®; system V: PGML®/Cremophor®/Transcutol® and 
system VI: PGML®/Tween 80®/Transcutol®. The phase diagrams are 
presented in figures 1-6. The shaded region indicates nanoemulsion 
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region. Wider region indicates better self-nanoemulsifying 
ability[18]. Ternary phase behavior investigations help to choose the 
proper concentration of excipients, i. e., oil proportion and optimum 
S/CoS ratio in the formulation to produce emulsions with good 
stability [19]. 
 
Table 1: Solubility of sertraline HCl in various oils, surfactants 
and cosurfactants 
Components Solubility (mg/ml) 
Capmul 10.51 ® 
Captex 13.00 ® 
PGML 21.87 ® 
Capryol 0.16 ® 
Labrafil 0.62 ® 
Cremophor 32.50 ® 
Tween 80 59.40 ® 
Polyethylene glycol 7.45 
Propylene glycol 10.65 
Transcutol 29.41 ® 
 
 
Fig. 1: Ternary phase diagram of SNEDDS containing Capmul®, 
Cremophor® and Transcutol®
 
Fig. 2: Ternary phase diagram of SNEDDS containing Capmul
 (gray domain indicates the region 




Tween 80® and Transcutol®
 
 (gray domain indicates the region 
of self emulsification and black circles represent the stable 
formulations) 
 
Fig. 3: Ternary phase diagram of SNEDDS containingCaptex®, 
Cremophor® and Transcutol®
 
Fig. 4: Ternary phase diagram of SNEDDS containing Capmul
 (black circles represent the stable 
formulations) 
®, 
Tween 80® and Transcutol®
 
Fig. 5: Ternary phase diagram of SNEDDS containing PGML
 (gray domain indicates the region 






Fig. 6: Ternary phase diagram of SNEDDS containing PGML
 (gray domain indicates the region 




Tween 80® and Transcutol®
When Capmul
 (black circles represent the stable 
formulations) 
 
In the current investigation, it could be seen that the system I shows 
the widest nanoemulsification region followed by systems II, III and 
IV, which showed the same area of nanoemulsification region. 
Systems V and VI show the least area of nanoemulsification region. 
® is used as the oil phase with Cremophor®; surfactant, 
the nanoemulsion area is much larger than that with Tween 80®. 
Cremophor®
20
is a good emulsifier for the drug used in nanoemulsion, 
it may provide reduction in the surface tension and fluidizes the 
interfacial surfactant film which can expand the area of existence of 
microemulsion system [ ]. Also Capmul®, a medium chain 
monoglyceride, is likely to increase the interfacial fluidity of 
surfactant boundaries in the micelles because of the entrapment of 
Capmul®
21
 in the high HLB surfactant, enhancing the emulsification 
process upon dilution with aqueous medium [ ]. It was reported 
that medium chain monoglycerides (polar lipids) promote water 
penetration and self dispersibility of lipid formulations and have 
good solvent capacity for drugs [22]. 
The present study indicates that Cremophor® has better ability to 
emulsify PGML® than Tween 80®. Although, HLB values of both 
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surfactants used in the study are greater than 10, there is considerable 
difference in their ability to emulsify oils. Results obtained indicate that 
apart from HLB value, other factors such as the structure and the relative 
length of hydrophobic chains of surfactants influence 
nanoemulsification. These results are in conformation with results 
reported in literature [23].  The systems I, II, III and IV were selected 
based on the ability of the prepared ternary systems to form 
nanoemulsion containing the highest oil content (table 2). 
Characterization of SNEDDS 
Thermodynamic stability test 
Thermodynamic stability studies were performed to observe the 
ability of the formulation to withstand different stress conditions. A 
stable SNEDDS formulation should not lose its ability of spontaneous 
emulsification upon dilution. All liquid formulations are found to be 
stable in the centrifugation test and in the freeze thaw cycle. There is 
no sign of phase separation. Results are shown in table 3. 
Cloud point measurement 
The cloud point is the temperature above which the formulation 
clarity turns into cloudiness. At higher temperatures, irreversible 
phase separation can occur due to dehydration of polyethylene oxide 
moiety of non-ionic surfactant and the cloudiness of the preparation 
would have a bad effect on drug absorption. Since both drug 
solubilization and formulation stability will decline with this phase 
separation, the cloud point of the formulation should be over 37 0
15
C. 
The cloud point value is affected by factors such as drug 
hydrophobicity, kind, combination, mixing ratio and amount of each of 
the oils, surfactants and cosurfactants used [ ]. In this study, cloud 
points of all formulations are high. Results contented the stability of 
formulations towards separation in the GIT temperature (table 3). 
Determination of the emulsification time 
The rate of emulsification was taken as an important index for the 
assessment of the efficiency of self-emulsification that is the SNEDDS 
should disperse completely and quickly when subjected to dilution 
under mild agitation[24, 25]. All the formulations exhibited a rapid 
rate of emulsification ranging from 10 to 39 s (Table 3). It is obvious 
that rapid emulsification is correlated with lower content of oil and 
higher content of Smix which results in lower viscosity of the system 
[25].  An attempt to find an adequate mathematical model between 
emulsification time and SNEDDS formulations failed. Gao et 
al.[26]reported a failed attempt to find an adequate mathematical model 
between droplet size and a SNEDDS formulation consisting of glycerol 
dioleate, glycerol monooleate, Cremophor®
Formula 
, and PEG 400. 
 
Table 2: Composition of the prepared SNEDDS (%w/w) 
Smix ratio Capmul Captex® PGML® Cremophor® Tween 80 ® Transcutol® 
F1  1:1 10    45   45  
F2 2:1 10    60   30  
F3 3:1 10    67.5   22.5  
F4 4:1 10    72   18  
F5 1:1 20    40   40  
F6 2:1 20    53.4   26.6  
F7 3:1 20    60   20  
F8 4:1 20    64   16  
F9 1:1 10     45  45  
 F10 2:1 10     60  30  
 F11 3:1 10     67.5  22.5  
 F12 4:1 10     72  18  
 F13 1:1   10  45   45  
 F14 2:1   10  60   20  
 F15 3:1   10  67.5   22.5  
 F16 4:1   10  72   18  
 F17 1:1  10    45  45  
 F18 2:1  10    60  20  
F19 3:1  10    67.5  22.5  
F20 4:1  10    72  18  
 
Table 3: Physicochemical properties of liquid SNEDDS 
Formulation Centrifugation test Freeze thaw cycle Precipitation 
After 6 h 
Cloud point (Temp°C) Self-emulsification time (s) 
F1 √ √ √ 72 15 
F2 √ √ √ 85 12 
F3 √ √ √ 82 10 
F4 √ √ √ 76 11 
F5 √ √ √ 74 23 
F6 √ √ √ 90 25 
F7 √ √ √ 92 24 
F8 √ √ √ 75 18 
F9 √ √ √ 71 17 
F10 √ √ √ 86 22 
F11 √ √ √ 92 10 
F12 √ √ √ 84 12 
F13 √ √ √ 77 15 
F14 √ √ √ 79 27 
F15 √ √ √ 81 29 
F16 √ √ √ 86 13 
F17 √ √ √ 90 10 
F18 √ √ √ 87 28 
F19 √ √ √ 76 29 
F20 √ √ √ 71 16 
where, √- Passed and x- Failed 
 
 
Droplet size, particle size distribution and zeta potential analysis  
The droplet size of the nanoemulsion is a crucial factor in self- 
emulsification performance because it determines the rate and 
extent of drug release, as well as absorption [27]. The 
significance of emulsion droplet size in the in vivo performance 
of the formulation is not yet clear. Tarr and Yalkowsky[28]have 
demonstrated enhancement of the rate of intestinal absorption 
of cyclosporine through the reduction of the emulsion droplet 
size.  
One possible explanation of the enhanced absorption observed with 
the small particle size is the larger surface area available for 
partitioning of the drug and for lipase activity. However, we fully 
agree to a recent statement by Pouton[29], that the role of droplet 
size is less important than it was assumed by some authors due to 
the fact that digestion will take place directly after the lipid 
dispersion leaves the stomach and at this stage particle size will 
have no or little effect. The results of droplet size determination and 
zeta potential of the different SNEDDS are shown in table 4. 
 
Table 4: Globule size, PDI and Zeta potential of liquid SNEDDS 
Formulation Globule size (nm) PDI Zeta potential 
F1 24.77 ± 2.56 0.71 -12.90 
F2 25.43 ± 1.79 0.27 -10.96 
F3 58.35 ± 1.18 0.30 -10.56 
F4 70.42 ± 9.78 0.39 -15.23 
F5 31.50 ± 3.69 0.33 -11.60 
F6 20.10 ± 1.93 0.26 -11.26 
F7 88.08 ± 1.62 0.50 -7.53 
F8 92.46 ± 6.64 0.53 -9.64 
F9 43.73 ± 5.78 0.33 -14.40 
F10 29.20 ± 9.19 0.20 -11.19 
F11 96.35 ± 16.12 0.31 -11.72 
F12 120.15 ± 13.08 0.27 -12.10 
F13 23.70 ± 4.52 0.49 -10.12 
F14 26.64 ± 6.10 0.37 -11.20 
F15 49.13 ± 2.31 0.43 -7.92 
F16 58.00 ± 2.78 0.38 -9.93 
F17 51.14 ± 7.78 0.32 -6.65 
F18 49.55 ± 2.73 0.30 -9.50 
F19 48.14 ± 3.34 0.27 -7.16 
F20 64.29 ± 7.53 0.80 -7.77 
 
Globule size of all formulations is in the range of 20.10-153.95 nm. 
Polydispersity index was determined which measures the spread of 
the particle-size distribution, in which a small value indicates a 
narrow particle-size range[30]. In general, the SNEDDS formulations 
exhibit a relatively limited size distribution, indicating a close size 
distribution. 
Upon statistical analysis, there is no significant difference between 
the average globule size of all the four systems (P >0.05). However, 
in system I, F1 and F2 show significant decrease in globule size 
compared to F3, F4, F5, F6, F7 and F8 (P ˂ 0.05). In system II, F10 
shows significant decrease (P ˂0.05) in globule size compared to F9, 
F11 and F12. In system III, F14 shows significant decrease in globule 
size compared to F13, F15 and F16 (P ˂0.05). In System IV, F18 and 
F19 show significant decrease in globule size compared to F17 and 
F20 (P ˂0.05).  
As described in literature, an increase in surfactant concentration 
results in the decrease in the droplet size, but this phenomenon 
levels off at a particular surfactant concentration, whereby any 
further increase in surfactant concentration results in a raise in 
droplet size [31]. Stabilization of oil droplets by virtue of decrease in 
droplet size can be attributed to localization of surfactant monolayer 
at the oil–water interface [32]. However, further rise in surfactant 
concentration leads to increased penetration of water into oil 
droplets causing breakdown of oil droplets and resulting in bigger 
droplets [16]. 
From the above analysis, it can be concluded that in most systems, 
the formula containing Smix ratio 1:1 or 2:1 shows the least globule 
size compared to the formulae containing Smix ratios 3:1 and 4:1. 
The reason may be due to higher surfactant concentration that 
results in more rapid maturation of the droplets. 
The charge of oil droplets of SNEDDS is another property that should 
be assessed for increased absorption [31]. The charge of the oil 
droplets in SNEDDS is negative due to the presence of free fatty 
acids.  
The significance of zeta potential is that it can be related to the 
stability of colloidal dispersions. Zeta potential indicates degree of 
repulsion between adjacent, similarly charged particles in 
dispersion. For molecules that are small enough, a high zeta 
potential will confer stability, i. e., the solution or dispersion will 
resist aggregation. Zeta potential controls charge interactions. 
Conventionally, a high zeta potential can be high in positive or 
negative sense, i. e., −30mV or +30mV would be considered as high 
zeta potential. Negative values of zeta potential of the optimized 
formulations indicate that the formulations are negatively charged 
and high values of zeta potential of all the formulations signify 
stability of the system [14]. 
Upon statistical analysis, there is no significant difference between 
the zeta potential of the SNEDDS formulations (P >0.05). 
According to the above results, F2, F6, F10, F14 and F19 were 
chosen for further investigation as they showed the smallest globule 
size. 
Morphological characterization 
Transmission electron microscopy is the most important technique 
for the study of microstructures, because it directly produces images 
at high resolution and it can capture any coexistent structures and 
microstructure transitions [33]. Morphology and structure of the 
optimized nanoemulsion formulations were determined using 
transmission electron microscopy (figure 7).  
Combination of bright field imaging at increasing magnification and 
of diffraction modes was used to reveal the form and size of the 
nanoemulsion. The nanoemulsion droplets appear as dark and the 
surroundings were bright. Globules were seen as uniform in size and 
spherical in shape which indicates the good state of nanoemulsion.  
Drug content 
The drug content of sertraline HCl SNEDDS formulation was 
measured using UV spectroscopic method.  
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The drug content is determined by considering 25 mg of drug as 
100%. All are in specified limit (97 %-101 %) of drug content 
(table 5). 
In vitro drug release study 
The  In vitro dissolution studies were also performed in order to 
ensure the quick release of the drug in the dissolution medium and 
they act as an important quality control tool for the dosage forms. 
Furthermore,  In vitro dissolution studies also give an idea about the 
self-nanoemulsification efficiency of the developed system [34]. The 
results of sertalineHCl release from the prepared SNEDDS and plain 
drug are shown in table 6 and graphically illustrated in figure 8. 
The release efficiency of drug from the SNEDDS formulations was 
significantly higher (p < 0.05) than the plain drug. This could be 
attributed to the small globule in case of nanoemulsion formulations 
which provided large surface area for the release of drug and thus 
permitting faster rate of drug release.  
These results confirm the role of SNEDDS formulation to improve 












Fig. 7: Transmision electron microscopy of: (1) F2; (2) F6; (3) F10; (4) F14 and (5) F9 
 
Table 5: Drug content of sertraline HCl in F2, F6, F10, F14 and F19 
Formulation Percent drug content (mean ± SD) from SNEDDS 
F2 97.15 ± 2.15 
F6 99.20 ± 3.78 
F10 100.86 ± 5.91 
F14 98.71 ± 2.46 
F19 97.56 ± 5.74 
 
Table 6: Release of sertraline HCl from F2, F6, F10, F14, F19 and the drug per se 
Time 
(min) 
Percent cumulative drug released (mean ± SD) from SNEDDS: 
Plain drug F2 F6 F10 F14 F19 
5 42.26 ± 2.54 42.00 ± 3.60 36.60 ± 5.40 15.60 ± 2.40 39.60 ± 2.40 96.00 ± 0.09 
10 46.80 ± 3.47 55.43 ± 3.62 65.60 ± 1.77 15.08 ± 1.81 50.02 ± 0.61 98.19 ± 0.02 
15 58.09 ± 7.56 79.74 ± 6.04 73.16 ± 1.82 19.37 ± 1.22 54.49 ± 1.21 100.00 ± 0.05 
30 62.01 ± 8.50 88.58 ± 7.27 80.17 ± 4.77 100.67 ± 6.25 100.30 ± 5.42 100.00 ± 0.97 
45 71.95 ± 6.47 92.66 ± 7.91 87.81 ± 1.19 100.65 ± 2.97 100.43 ± 0.05 100.00 ± 0.07 
60 74.75 ± 3.71 93.17 ± 6.15 100.89 ± 6.59 100.53 ± 1.18 100.10 ± 0.05 100.00 ± 0.04 
Release efficiency (%) 59.94 ± 5.21 78.36 ± 6.17 75.31 ± 1.60 80.38 ± 0.32 79.05 ± 0.45 95.15 ± 0.50 
 
In this study, sertraline HCl was formulated as SNEDDS in an 
attempt to increase its solubility and enhance its release. Screening 
of surfactants and cosurfactants studies helped to identify the most 
suitable excipients, whereas the phase diagrams gave a good idea 
about the concentrations of the nanoemulsion components that 
should be employed to achieve self-nanoemulsifying formulations. 
All the prepared SNEDDS were thermodynamically stable and 
globule size of all formulations was in the range of 20.10-153.95 nm. 
There was no significant difference between the average globule size 
of all the four systems (P >0.05). The prepared SNEDDS showed 
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significant increase in the release profile when compared to plain 
drug. These results may shed a strong beam of light on the 
potentiality of utilizing SNEDDS for improving the biological 
performance of sertraline HCl. 
 
 
Fig. 8: Release profile of sertraline HCl from F2, F6, F10, F14, 
F19 and plain drugCONCLUSION 
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